Skip to main content
Erschienen in: International Journal of Hematology 4/2014

01.04.2014 | Original Article

Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning

verfasst von: Katsuji Kaida, Kazuhiro Ikegame, Junko Ikemoto, Rie Murata, Reiko Irie, Satoshi Yoshihara, Shinichi Ishii, Masaya Okada, Takayuki Inoue, Hiroya Tamaki, Toshihiro Soma, Yoshihiro Fujimori, Shunro Kai, Hiroyasu Ogawa

Erschienen in: International Journal of Hematology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

In the present study, we analyzed the kinetics of serum soluble interleukin-2 receptor (sIL-2R) using data from 77 patients undergoing HLA-haploidentical transplantation using reduced-intensity conditioning (RIC), who were at an advanced stage or at high risk for relapse, to clarify the usefulness of sIL-2R as a biomarker of acute graft-versus-host disease (GVHD). Anti-T-lymphocyte globulin and methylprednisolone were used as GVHD prophylaxis. While the median sIL-2R in 38 patients not developing GVHD was suppressed at levels <740 U/ml, sIL-2R in 25 patients developing severe GVHD peaked on day 11 (1,663 U/ml), and thereafter decreased to <1,000 U/ml after day 30. The occurrence of GVHD was not limited to times of high sIL-2R level, but occurred at any time point on the sIL-2R curve. Most patients developing GVHD, however, experienced a higher sIL-2R level early in their transplant course. The combination of RIC and glucocorticoids sufficiently suppressed sIL-2R levels after HLA-haploidentical transplantation. In a multivariate analysis to identify factors associated with GVHD, day 7 sIL-2R >810 U/ml was the only factor significantly associated with the occurrence of severe GVHD (p = 0.0101).
Literatur
1.
2.
Zurück zum Zitat Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–54.PubMedCrossRef Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–54.PubMedCrossRef
3.
Zurück zum Zitat Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117:3921–8.PubMedCrossRef Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117:3921–8.PubMedCrossRef
4.
Zurück zum Zitat Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–73.PubMedCrossRef Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–73.PubMedCrossRef
5.
Zurück zum Zitat Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008;36:1–8.PubMedCrossRef Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008;36:1–8.PubMedCrossRef
6.
Zurück zum Zitat Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282–8.PubMedCentralPubMedCrossRef Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282–8.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011;118:2609–17.PubMedCrossRef Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011;118:2609–17.PubMedCrossRef
8.
Zurück zum Zitat Diamantstein T, Osawa H. The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-interleukin-2 receptor monoclonal antigen. Immunol Rev. 1986;92:5–27.PubMedCrossRef Diamantstein T, Osawa H. The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-interleukin-2 receptor monoclonal antigen. Immunol Rev. 1986;92:5–27.PubMedCrossRef
9.
Zurück zum Zitat Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol. 1993;11:245–68.PubMedCrossRef Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol. 1993;11:245–68.PubMedCrossRef
10.
Zurück zum Zitat Junghans RP, Waldmann TA. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med. 1996;183:1587–602.PubMedCrossRef Junghans RP, Waldmann TA. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med. 1996;183:1587–602.PubMedCrossRef
11.
Zurück zum Zitat Robb RJ, Kutny RM. Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol. 1987;139:855–62.PubMed Robb RJ, Kutny RM. Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol. 1987;139:855–62.PubMed
12.
Zurück zum Zitat Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113:273–8.PubMedCentralPubMedCrossRef Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113:273–8.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Siegert W, Josimovic-Alasevic O, Schwerdtfeger R, Baurmann H, Schmidt CA, Musch R, et al. Soluble interleukin-2 receptors in patients after bone marrow transplantation. Bone Marrow Transpl. 1990;6:97–101. Siegert W, Josimovic-Alasevic O, Schwerdtfeger R, Baurmann H, Schmidt CA, Musch R, et al. Soluble interleukin-2 receptors in patients after bone marrow transplantation. Bone Marrow Transpl. 1990;6:97–101.
14.
Zurück zum Zitat Miyamoto T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transpl. 1996;17:185–90. Miyamoto T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transpl. 1996;17:185–90.
15.
Zurück zum Zitat Foley R, Couban S, Walker I, Greene K, Chen CS, Messner H, et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation. Bone Marrow Transpl. 1998;21:769–73.CrossRef Foley R, Couban S, Walker I, Greene K, Chen CS, Messner H, et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation. Bone Marrow Transpl. 1998;21:769–73.CrossRef
16.
Zurück zum Zitat Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantation as a marker for GVHD. Bone Marrow Transpl. 1998;21:29–32.CrossRef Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantation as a marker for GVHD. Bone Marrow Transpl. 1998;21:29–32.CrossRef
17.
Zurück zum Zitat Kami M, Matsumura T, Tanaka Y, Mikami Y, Miyakoshi S, Ueyama J, et al. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease. Leuk Lymphoma. 2000;38:533–40.PubMedCrossRef Kami M, Matsumura T, Tanaka Y, Mikami Y, Miyakoshi S, Ueyama J, et al. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease. Leuk Lymphoma. 2000;38:533–40.PubMedCrossRef
18.
Zurück zum Zitat Ogawa H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, et al. Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation. Transplantation. 2004;78:488–9.PubMedCrossRef Ogawa H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, et al. Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation. Transplantation. 2004;78:488–9.PubMedCrossRef
19.
Zurück zum Zitat Ikegame K, Kawakami M, Yamagami T, Maeda H, Onishi K, Taniguchi Y, et al. HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimerism. Clin Lab Haematol. 2005;27:1–3.CrossRef Ikegame K, Kawakami M, Yamagami T, Maeda H, Onishi K, Taniguchi Y, et al. HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimerism. Clin Lab Haematol. 2005;27:1–3.CrossRef
20.
Zurück zum Zitat Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transpl. 2009;15:61–72.CrossRef Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transpl. 2009;15:61–72.CrossRef
21.
Zurück zum Zitat Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom RA, et al. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation. 1989;47:77–81.PubMedCrossRef Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom RA, et al. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation. 1989;47:77–81.PubMedCrossRef
22.
Zurück zum Zitat Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, Tomonaga M. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer. 1994;73:2753–8.PubMedCrossRef Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, Tomonaga M. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer. 1994;73:2753–8.PubMedCrossRef
23.
Zurück zum Zitat Kalmanti M, Karamolengou K, Dimitriou H, Tosca A, Vlachonikolis I, Peraki M, et al. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma. Int J Hematol. 1993;57:147–52.PubMed Kalmanti M, Karamolengou K, Dimitriou H, Tosca A, Vlachonikolis I, Peraki M, et al. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma. Int J Hematol. 1993;57:147–52.PubMed
24.
Zurück zum Zitat Pui CH, Ip SH, Iflah S, Behm FG, Grose BH, Dodge RK, et al. Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood. 1988;71:1135–7.PubMed Pui CH, Ip SH, Iflah S, Behm FG, Grose BH, Dodge RK, et al. Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood. 1988;71:1135–7.PubMed
25.
Zurück zum Zitat Cimino G, Amadori S, Cava MC, De Sanctis V, Petti MC, Di Gregorio AO, et al. Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients. Leukemia. 1991;5:32–5.PubMed Cimino G, Amadori S, Cava MC, De Sanctis V, Petti MC, Di Gregorio AO, et al. Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients. Leukemia. 1991;5:32–5.PubMed
26.
Zurück zum Zitat Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host diseases in human recipients of marrow from HLA matched sibling donors. Transplantation. 1974;18:295–304.PubMedCrossRef Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host diseases in human recipients of marrow from HLA matched sibling donors. Transplantation. 1974;18:295–304.PubMedCrossRef
27.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.CrossRef Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.CrossRef
28.
Zurück zum Zitat Kanda J, Atsuta Y, Wake A, Ichinohe T, Takanashi M, Morishima Y, et al. Impact of the direction of HLA mismatch on transplantation outcomes in single unrelated cord blood transplantation. Biol Blood Marrow Transpl. 2013;19:247–54.CrossRef Kanda J, Atsuta Y, Wake A, Ichinohe T, Takanashi M, Morishima Y, et al. Impact of the direction of HLA mismatch on transplantation outcomes in single unrelated cord blood transplantation. Biol Blood Marrow Transpl. 2013;19:247–54.CrossRef
29.
Zurück zum Zitat Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118:6702–8.PubMedCentralPubMedCrossRef Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118:6702–8.PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2:13ra2.PubMedCentralPubMedCrossRef Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2:13ra2.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Paczesny S, Raiker N, Brooks S, Mumaw C. Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol. 2013;98:275–92.PubMedCrossRef Paczesny S, Raiker N, Brooks S, Mumaw C. Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol. 2013;98:275–92.PubMedCrossRef
32.
Zurück zum Zitat Ferrara JL, Levy R, Chao NJ. Pathophysiology mechanism of acute graft-vs.-host disease [review]. Biol Blood Marrow Transpl. 1999;5:347–56.CrossRef Ferrara JL, Levy R, Chao NJ. Pathophysiology mechanism of acute graft-vs.-host disease [review]. Biol Blood Marrow Transpl. 1999;5:347–56.CrossRef
Metadaten
Titel
Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning
verfasst von
Katsuji Kaida
Kazuhiro Ikegame
Junko Ikemoto
Rie Murata
Reiko Irie
Satoshi Yoshihara
Shinichi Ishii
Masaya Okada
Takayuki Inoue
Hiroya Tamaki
Toshihiro Soma
Yoshihiro Fujimori
Shunro Kai
Hiroyasu Ogawa
Publikationsdatum
01.04.2014
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2014
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1542-x

Weitere Artikel der Ausgabe 4/2014

International Journal of Hematology 4/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.